PET-CT highly accurate for detecting ovarian cancer recurrenceMay 02, 2006The accuracy of PET-CT for detecting recurrent ovarian cancer is high, more accurate even than either CT or PET alone, says a new study by researchers from Massachusetts General Hospital in Boston. For the study, the researchers reviewed 54 body CT, PET and PET-CT examinations on 53 patients with ovarian cancer who were being evaluated for tumor recurrence. The researchers found that PET-CT demonstrated an improved accuracy (49/53, 92%) over CT alone (44/53, 83%) and over PET alone (41/53, 77%). "We undertook this study because PET-CT is a hot and emerging imaging technique, and its use continues to be evaluated for many indications in the abdomen and pelvis. Also, on CT it is difficult many times to detect ovarian cancer recurrence because of the presence of certain metastatic deposits," said Sunit Sebastian, MD, who is currently at Emory University School of Medicine and is lead author on the study. According to the researchers, the results of their study could mean earlier and more definitive detection of recurrent ovarian cancer. "When you combine the advantages of the excellent anatomical depiction that CT gives us and the amount of functional information that PET give us, doctors are better able to monitor cancer patients and manage their treatment accordingly," said Dr. Sunit Sebastian. The full results of the study will be presented on May 2, 2006 during the American Roentgen Ray Society Annual Meeting in Vancouver, BC. American Roentgen Ray Society |
|||||||||||||||||||||
| Related Ovarian Cancer Current Events and Ovarian Cancer News Articles FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible. Metals could forge new cancer drug Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds. Breast cancer patients with high risk gene diagnosed 6 years earlier than generation before Women with a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas M. D. Anderson Cancer Center. Cancer Predisposition From Gene Variant Shows Strong Gender Bias Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated. Medications Effective in Reducing Risks for Breast Cancer Can Also Cause Serious Side Effects Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health & Human Services. Scientists from University of Hawaii at Manoa find genetic marker A new genetic marker associated with ovarian cancer risk was recently discovered by an international research group, led by scientists from the Cancer Research Genetic Epidemiology Unit in the United Kingdom. New treatment in sight for ovarian cancer In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. Young early stage ovarian cancer patients can preserve fertility A new study finds that young women with early-stage ovarian cancer can preserve future fertility by keeping at least one ovary or the uterus without increasing the risk of dying from the disease. Estrogen-Dependent Switch Tempers Killing Activity of Immune Cells The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses. More Ovarian Cancer Current Events and Ovarian Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||